China's WuXi explores sale of pharma operations as US restrictions loom, FT reports By Reuters
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 03 2024
0mins
Source: Investing.com
WuXi AppTec and WuXi Biologics Operations Sale: The Chinese biotech companies are planning to sell parts of their operations, including WuXi AppTec's cell and gene therapy unit in Philadelphia, due to U.S. national security concerns.
U.S. Legislation Against Chinese Biotech: A bill passed by the U.S. House aims to restrict business with WuXi AppTec and similar companies, which has been criticized by China's foreign ministry as discriminatory.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
